{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T03:02:25Z","timestamp":1779678145106,"version":"3.53.1"},"reference-count":18,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Liver metastases from breast cancer (BCLM) are associated with poor prognosis and represent a significant clinical challenge in the era of modern systemic therapies. Local ablative therapies (LATs), including microwave ablation (MWA) and transarterial chemoembolization (TACE), have emerged as potentially beneficial locoregional approaches in selected patients. However, data on survival outcomes and prognostic determinants of LAT in BCLM remain limited. This study aimed to evaluate the survival outcomes and prognostic factors of LAT in patients with breast cancer liver metastases at a tertiary care center. Methods: Patients with de novo or metachronous breast cancer liver metastases who underwent LAT (MWA and\/or TACE) between 2013 and October 2023 at a single tertiary center were retrospectively analyzed. Primary endpoints were overall survival (OS), defined as the time from LAT initiation to death from any cause, and progression-free survival (PFS), defined as the time from LAT initiation to the first radiographically confirmed progression. Treatment response was assessed per RECIST 1.1 criteria. Results: A total of 20 female patients were included. Median age at diagnosis was 42 years (IQR: 37\u201353). The majority had invasive ductal carcinoma (90%) and grade 3 disease (60%). Hormone receptor-positive, HER2-positive, and triple-negative subtypes comprised 45%, 25%, and 30% of the cohort, respectively. MWA was performed in 16 patients (80%), TACE was performed in 2 patients (10%), and both modalities were performed in 2 patients (10%). Complete response per RECIST 1.1 was achieved in 40% of patients. No grade 3\u20134 adverse events were recorded. Median OS was 20 months (95% CI: 14.9\u201325.1), and median PFS was 6 months (95% CI: 0\u201317.5). In univariate analysis, factors associated with improved OS included LM size &lt; 18 mm (23 vs. 11 months, p &lt; 0.001), unilateral lobar involvement (23 vs. 5 months, p = 0.025), and LAT application during first-line therapy (48 vs. 19 months, p = 0.021). Factors associated with improved PFS included LM size &lt; 18 mm (19 vs. 5 months, p &lt; 0.001) and achievement of complete ablative response per RECIST 1.1 (18 vs. 5 months, p = 0.005). Conclusions: LAT is a safe and feasible treatment modality in selected BCLM patients. In univariate analysis, smaller lesion size, unilateral hepatic involvement, and early-line LAT applications are associated with improved OS, while complete ablative response is associated with improved PFS. These findings warrant validation in prospective studies with larger cohorts. Multidisciplinary patient selection is essential to optimize outcomes.<\/jats:p>","DOI":"10.3390\/jcm15114045","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:45:08Z","timestamp":1779673508000},"page":"4045","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Local Ablative Therapy in Breast Cancer Liver Metastases: Survival Outcomes and Prognostic Factors\u2014A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1991-6620","authenticated-orcid":false,"given":"Elif","family":"Sertesen \u00c7am\u00f6z","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Bayrak","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Kara\u00e7in","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eahap","family":"T\u00f6renek","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-5789","authenticated-orcid":false,"given":"\u0130lknur","family":"Delikta\u015f Onur","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"\u00d6nder","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zt\u00fcrk","family":"Ate\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Xiao, Q., Zhang, W., Jing, J., Zhong, T., Li, D., Zhou, J., Liu, P., Duan, Z., Gao, H., and Shen, L. (2023). Patterns of de novo metastasis and survival outcomes by age in breast cancer patients: A SEER population-based study. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1184895"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.2147\/CMAR.S178395","article-title":"Incidence and prognostic factors of patients with synchronous liver metastases upon initial diagnosis of breast cancer: A population-based study","volume":"10","author":"Zhao","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ji, L., Cheng, L., Zhu, X., Gao, Y., Fan, L., and Wang, Z. (2021). Risk and prognostic factors of breast cancer with liver metastases. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07968-5"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.hoc.2024.08.012","article-title":"Surgical management of breast cancer liver metastasis","volume":"39","author":"Selby","year":"2025","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/jnci\/djq029","article-title":"International guidelines for management of metastatic breast cancer: Can metastatic breast cancer be cured?","volume":"102","author":"Pagani","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.3748\/wjg.v22.i16.4211","article-title":"Lymphocyte-to-monocyte ratio predicts survival after radiofrequency ablation for colorectal liver metastases","volume":"22","author":"Facciorusso","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1148\/radiol.2533081968","article-title":"Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation\u2014Intermediate and long-term survival rates","volume":"253","author":"Meloni","year":"2009","journal-title":"Radiology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/02656736.2018.1488279","article-title":"Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer","volume":"35","author":"Bai","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Narayanan, G., Ruiz, E.M., Dijkstra, M., Gentile, N.T., Donahue, D., Gandhi, R.T., Mahtani, R.L., Mautner, S., and van den Bemd, B.A.T. (2025). Clinical efficacy of percutaneous image-guided ablation in breast cancer metastases to the liver. Cancers, 17.","DOI":"10.3390\/cancers17233823"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.breast.2022.12.035","article-title":"Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes","volume":"67","author":"Glemarec","year":"2023","journal-title":"Breast"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Seidensticker, M., Garlipp, B., Scholz, S., Mohnike, K., Popp, F., Steffen, I., Seidensticker, R., St\u00fcbs, P., Pech, M., and Powerski, M. (2015). Locally ablative treatment of breast cancer liver metastases: Identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1499-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hpb.12133","article-title":"A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver","volume":"15","author":"Aksoy","year":"2013","journal-title":"HPB"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4045\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T02:05:27Z","timestamp":1779674727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/11\/4045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15114045"],"URL":"https:\/\/doi.org\/10.3390\/jcm15114045","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]}}}